Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period, compared to the consensus estimate of 1.090. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.4 million. Simulations Plus also updated its FY25 guidance to $1.07-1.20 EPS.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp increased their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.40.

Simulations Plus Trading Down 3.8 %

Shares of SLP traded down $0.95 during mid-day trading on Thursday, reaching $23.82. The company’s stock had a trading volume of 353,261 shares, compared to its average volume of 175,221. Simulations Plus has a 1-year low of $23.00 and a 1-year high of $51.22. The business has a 50-day simple moving average of $30.38 and a two-hundred day simple moving average of $30.38. The stock has a market cap of $478.59 million, a P/E ratio of 59.55 and a beta of 0.89.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The company had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company’s revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 earnings per share. Research analysts anticipate that Simulations Plus will post 1.09 EPS for the current year.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.